Vistin Pharma ASALTS:0RAM 77 5-Year Yield-on-Cost % is 4.83 as of Jul. 07, 2026, which is 7% above its 10-year median of 4.53. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.62 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 518 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 72.2% on this metric.
Vistin Pharma ASA's yield on cost for the quarter that ended in Mar. 2026 was 4.83.
The historical rank and industry rank for Vistin Pharma ASA's 5-Year Yield-on-Cost % or its related term are showing as below:
LTS:0RAM'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.08 Med: 4.53 Max: 9.22
Current: 4.83
During the past 13 years, Vistin Pharma ASA's highest Yield on Cost was 9.22. The lowest was 2.08. And the median was 4.53.
LTS:0RAM's 5-Year Yield-on-Cost % is ranked better than 72.2% of 518
companies
in the Drug Manufacturers industry
Industry Median: 2.265
vs LTS:0RAM: 4.83
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Vistin Pharma ASA 5-Year Yield-on-Cost % Related Terms
LTS:0RAM vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Vistin Pharma ASA (LTS:0RAM) has a 5-Year Yield-on-Cost % of 4.83 as of Jul. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vistin Pharma ASA and its competitors. This is near median its historical median of 4.53. Over the past decade, Vistin Pharma ASA's 5-Year Yield-on-Cost % has ranged from 2.08 to 9.22. According to the industry distribution chart, Vistin Pharma ASA ranks #144 out of 518 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is Vistin Pharma ASA's 5-Year Yield-on-Cost % too high?
Vistin Pharma ASA's current 5-Year Yield-on-Cost % of 4.83 is near median its 10-year median of 4.53. Over the past 10 years, this metric has ranged from a low of 2.08 to a high of 9.22. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.27. Vistin Pharma ASA's value of 4.83 is 113.2% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #144 out of 518 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #144 out of 518 companies for 5-Year Yield-on-Cost %. This puts Vistin Pharma ASA in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.27. Vistin Pharma ASA's value of 4.83 is 113.2% above this benchmark. Historically, Vistin Pharma ASA's own 5-Year Yield-on-Cost % has ranged from 2.08 to 9.22 over the past decade. While the company's 10-year median is 4.53 vs. the industry median of 2.27, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.27, based on 518 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current 5-Year Yield-on-Cost % of 4.83 is 113.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current 5-Year Yield-on-Cost % is 4.83, which is near median its own 10-year median of 4.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.62, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.83, which is near median its 10-year median of 4.53 and 113.2% above the Drug Manufacturers industry median of 2.27. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current 5-Year Yield-on-Cost % is 4.83 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.62.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
5-Year Yield-on-Cost %: 4.83 (near median its 10-year median of 4.53)
GF Value™: kr25.62 vs. price of kr20.70 (19.2% below fair value)
Industry Position: 113.2% above the Drug Manufacturers median (#144 of 518)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 